Meet Mark Welter
Mark Welter is the CEO of Oragen Technologies, Inc., a privately held biotechnology company headquartered in Des Moines, Iowa, with lab and manufacturing facilities in Ames, Iowa. The company’s primary focus is conducting discovery research to provide the health industry with unique animal vaccines and vaccine delivery systems. Founded in 1996, Oragen Technologies specializes in innovative solutions to animal disease.
More About Mark
Before Oragen Technologies in 1996, Mark Welter served as vice president of research and development at Ambico, Inc. in Dallas Center, Iowa, for over twenty years. In this capacity, he oversaw all virus, bacterial, and parasitic research, focusing on developing unique products for the international market.
Welter is widely known in the industry for his cutting-edge research aimed at preventing mucosal diseases. This research has resulted in numerous vaccines to help reduce infection in both pigs and cattle.
His major accomplishments include the development of rotavirus vaccines, including the first USDA-licensed rotavirus vaccine for use in swine. This is the only modified live rotavirus vaccine for any animal containing more than one strain.
Welter has also developed 15 federally licensed vaccines for swine and cattle. His work has been published in 17 professional journals. He has been awarded seven U.S. and three international patents.